# Margaret Shipp

> Mediated Wiki article. Canonical URL: https://mediated.wiki/source/Margaret_Shipp
> Markdown URL: https://mediated.wiki/source/Margaret_Shipp.md
> Source: https://en.wikipedia.org/wiki/Margaret_Shipp
> Source revision: 1340989704
> License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/)

{{Short description|American oncologist}}
{{Infobox academic
| name          =Margaret Shipp
| image          =
| image_size    = 230px 
| caption       =
| birth_date    =
| birth_place   =
| death_date    =
| education     =B.A., English and Biology, 1975, [Southern Methodist University](/source/Southern_Methodist_University) <br> MD, 1979, [Washington University School of Medicine](/source/Washington_University_School_of_Medicine)
| thesis_title   =
| thesis_year     =
| spouse        =
| children      = 
| website        = {{URL|shipplab.dfci.harvard.edu}}
| workplaces    =[Harvard Medical School](/source/Harvard_Medical_School) <br> [Dana–Farber Cancer Institute](/source/Dana%E2%80%93Farber_Cancer_Institute)
}}
'''Margaret Ann Shipp''' is an American hematologic oncologist. She is the Douglas S. Miller Chair in Hodgkin Lymphoma at [Harvard Medical School](/source/Harvard_Medical_School). Shipp is an elected Fellow of the [American Society for Clinical Investigation](/source/American_Society_for_Clinical_Investigation) and [National Academy of Medicine](/source/National_Academy_of_Medicine).

==Early life and education==
Shipp earned her [Bachelor of Arts](/source/Bachelor_of_Arts) degree in English and biology in 1975 from [Southern Methodist University](/source/Southern_Methodist_University). Following this, she completed her [medical degree](/source/medical_degree) at [Washington University School of Medicine](/source/Washington_University_School_of_Medicine) in 1979. Shipp then completed an internship and residency in internal medicine at [Barnes-Jewish Hospital](/source/Barnes-Jewish_Hospital).<ref>{{cite web |title=Margaret Ann Shipp MD |url=https://www.doximity.com/pub/margaret-shipp-md |website=doximity.com |access-date=June 6, 2021}}</ref>

==Career==
Upon graduating, Shipp joined the faculty at [Dana–Farber Cancer Institute](/source/Dana%E2%80%93Farber_Cancer_Institute) and [Harvard Medical School](/source/Harvard_Medical_School).  In 1996, Shipp was elected a Fellow of the [American Society for Clinical Investigation](/source/American_Society_for_Clinical_Investigation).<ref>{{cite web |title=Margaret Shipp, MD |url=https://www.the-asci.org/controllers/asci/AsciProfileController.php?pid=160385 |publisher=[American Society for Clinical Investigation](/source/American_Society_for_Clinical_Investigation) |access-date=June 6, 2021}}</ref> She was eventually named chief of the Division of Hematologic Neoplasia at Dana-Farber. In this role, she found a molecular "signature" in a form of lymphoma that identified patients unlikely to respond well to standard [chemotherapy](/source/chemotherapy), and who could benefit from treatment with certain experimental targeted drugs.<ref name="lymphoma">{{cite web |title=Predictive molecular signature in lymphoma may direct targeted therapy |url=https://www.dana-farber.org/newsroom/news-releases/2012/predictive-molecular-signature-in-lymphoma-may-direct-targeted-therapy/ |publisher=[Dana–Farber Cancer Institute](/source/Dana%E2%80%93Farber_Cancer_Institute) |access-date=June 6, 2021 |date=September 10, 2012}}</ref> Following this, Shipp's research team found that serum galectin-1 levels were "significantly associated with tumor burden and additional adverse clinical characteristics in newly diagnosed Hodgkin lymphoma (HL) patients." As such, they developed antibodies that recognize the galectin-1 protein and were used in developing the sandwich ELISA assay.<ref>{{cite web |title=Blood levels of immune protein predict risk in Hodgkin disease |url=https://www.eurekalert.org/pub_releases/2012-12/dci-blo121012.php |publisher=Eurekalert |access-date=June 6, 2021 |date=December 10, 2012}}</ref>

In 2014, as chief of the Division of Hematological Neoplasia at Dana-Farber and director of the Lymphoma Program at Dana-Farber/Harvard Cancer Center, Shipp was elected a member of the [National Academy of Medicine](/source/National_Academy_of_Medicine).<ref>{{cite web |title=Three Dana-Farber faculty elected to Institute of Medicine |url=https://www.dana-farber.org/newsroom/news-releases/2014/three-dana-farber-faculty-elected-to-institute-of-medicine/ |publisher=Dana–Farber Cancer Institute |access-date=June 6, 2021 |date=October 22, 2014}}</ref> Following her appointment, Shipp and her colleagues led a study on the successfulness of [nivolumab](/source/nivolumab), which prompted the [Food and Drug Administration](/source/Food_and_Drug_Administration) to designate it a "breakthrough therapy" for treating relapsed Hodgkin lymphoma.<ref>{{cite web |last1=Levy |first1=Robert |title=New Immunotherapy Breakthrough |url=https://hms.harvard.edu/news/new-immunotherapy-breakthrough |publisher=Harvard University |access-date=June 6, 2021 |date=December 6, 2014}}</ref> By the start of 2017, nivolumab had been FDA-approved for use on individuals with Hodgkin lymphoma, melanoma, non-small cell lung cancer, bladder cancer, kidney cancer, and squamous cell cancer of the head and neck.<ref>{{cite web |title=In Check: Attacking Cancer from Many Fronts |url=https://blog.dana-farber.org/insight/2017/06/in-check-attacking-cancer-from-many-fronts/ |publisher=Dana Farber Cancer Center |access-date=June 11, 2021 |date=June 27, 2017}}</ref> Following this, she oversaw a study showing that Hodgkin lymphomas frequently avoid immune detection by eliminating their MHC class I proteins.<ref>{{cite web |title=Study finds melanoma biomarkers predicting checkpoint blocker response |url=https://www.dana-farber.org/newsroom/news-releases/2018/study-finds-melanoma-biomarkers-predicting-checkpoint-blocker-response/ |publisher=Dana–Farber Cancer Institute |access-date=June 6, 2021 |date=July 18, 2018}}</ref>

During the [COVID-19 pandemic](/source/COVID-19_pandemic), Shipp and her colleague [Scott J. Rodig](/source/Scott_J._Rodig) earned a Blood Cancer Discoveries Grant to map the immune microenvironment in classical Hodgkin lymphoma.<ref>{{cite web |title=New 'Blood Cancer Discoveries Grant Program' supported by a novel 3-way collaboration |url=https://www.eurekalert.org/pub_releases/2020-07/ai-nc063020.php |website=eurekalert.org |publisher=Eurekalert |access-date=June 2, 2021 |date=July 1, 2020}}</ref> 
==References==
{{Reflist}}

{{Authority control}}

{{DEFAULTSORT:Shipp, Margaret}}
Category:Living people
Category:American women medical doctors
Category:American oncologists
Category:Harvard Medical School faculty
Category:Washington University School of Medicine alumni
Category:Members of the National Academy of Medicine
Category:Members of the American Society for Clinical Investigation
Category:Year of birth missing (living people)

---
Adapted from the Wikipedia article [Margaret Shipp](https://en.wikipedia.org/wiki/Margaret_Shipp) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/Margaret_Shipp?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.